Fact sheets

Malaria Fact sheets

Plasmodium vivax malaria

• Download (95 Kb .pdf file)

Plasmodium falciparum malaria

• Download (288 Kb .pdf file)

Malaria and the Military

• Download (123 Kb .pdf file)

Project Fact sheets

The PATH Malaria Vaccine Initiative

• Download (173 Kb .pdf file)

RTS,S Malaria Vaccine Clinical Trials

• Download (53 Kb .pdf file)

MAL-038 Trial of RTS,S

• Download (53 Kb .pdf file)

Sanaria Pf SPZ Malaria Vaccine Candidate

• Download (28 Kb .pdf file)

The PvRII Malaria Vaccine Candidate

• Download (33 kb .pdf file)

Development and Evaluation of an Adenovector-based Malaria Vaccine Candidate

• Download (34 Kb .pdf file)

Growth Inhibition Assay (GIA) Reference Center

• Download (27 Kb .pdf file)

Enzyme-Linked Immunosorbent Assay (ELISA) Service Center

• Download (27 Kb .pdf file)

Preparing for a Future Malaria Vaccine in Africa: The Malaria Vaccine Decision-Making Framework

• Download (35 Kb .pdf file)

Malaria Vaccine Technology Roadmap: Accelerating the Development of a Malaria Vaccine

• Download (45 Kb .pdf file)

MVI Partnership with the Malaria Vaccine Development Branch at the National Institute of Allergy and Infectious Diseases

• Download (33 Kb .pdf file)

Meeting Reports

9-10 December 2002
Malaria Liver-Stage Antigen Meeting Report

The purpose of this meeting was to discuss what is know about antigens of liver-stage parasites (e.g their biology and anti-plasmodial immune responses) and their potential use in vaccines.

• Download (542 Kb .pdf file)

Presentations

19 January 2005
Boston Consulting Group: Market Assessment for Malaria Vaccines

This presentation provides an in-depth look at the global market assessment of demand for malaria vaccines. Although we are likely years away from a licensed malaria vaccine, the malaria community requires improved information for decision-making. While the target population for a malaria vaccine is theoretically large—nearly 40 percent of the world’s population is at risk—the number of those who could pay for or would use a particular malaria vaccine is likely substantially lower. Understanding the components and dynamics of actual demand is critical to addressing current pressing issues in malaria vaccine development, and to ensuring that the introduction of a vaccine results in early, widespread use.

• Download (2,058 Kb .pdf file)

26 June 2003
BIO 2003 convenes workshop: Harnessing Medical Technology to Fight Global Diseases: Where Science and Advocacy Meet

Designed to update biotech companies on progress and opportunities for creating new tools to prevent AIDS, TB, and malaria, this workshop provided overviews on the state of research and development of HIV vaccines and microbicides, and vaccines for prevention of TB and malaria. It also gave an update on legislative and policy initiatives to harness expertise in pharmaceutical and biotech companies toward the accelerated development of these technologies.

Malaria Vaccines - Melinda Moree, Ph.D., Director, MVI, PATH

• Download (827 Kb .pdf file)

Microbicides - Polly Harrison, Ph.D., Director, Alliance for Microbicide Development

• Download (234 Kb .pdf file)

HIV Vaccines - David Gold, Global Health Strategies

• Download (472 Kb .ppt file)

Sequella - Carol A. Nacy, Ph.D., CEO, Sequella, Inc.

• Download (698 Kb .pdf file)

Legislative Agenda of the Prevention Technologies Working Group (excerpted from the AIDS Vaccine Advocacy Coalition)

• Download (106 Kb .pdf file)

21 November 2002
Malaria Vaccines 2002

Ripley Ballou, M.D., delivered the malaria vaccine plenary at the 3rd MIM Pan African Conference on Malaria. With his permission, his presentation on the current status of malaria vaccine development is available here.

• Download (505 Kb .pdf file)